EMA reviewing possible link between Johnson & Johnson vaccine and blood clots

1 minute read

 


The Chinese mainland recorded 10 confirmed cases on Saturday, all from overseas. 


Europe's medicine watchdog, the European Medicines Agency (EMA), said on Friday it was reviewing reports of rare blood clots in four people who received the COVID-19 vaccine developed by Janssen, the pharmaceutical arm of Johnson & Johnson.


Chinese vaccines Sinopharm and CoronaVac (Sinovac) are in the final stage of evaluation by the Emergency Use Listing of the World Health Organization (WHO), and a "final decision" should be made between April 26 and May 3, a WHO official said at a press conference on Friday.


Iran on Saturday enforced a 10-day restriction throughout the country to curb the recent resurgence of coronavirus cases and deaths. It's now facing the fourth wave of COVID-19 infection as its national caseload surpassed 2 million earlier this week.


Also Read: COVID-19: Things you know about AstraZeneca vaccine - Government recommendations


The number of confirmed COVID-19 cases worldwide has exceeded 135 million, with over 2.9 million deaths and more than 76 million recoveries, according to the latest data from Johns Hopkins University.